Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 5/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.34 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2958818 | 0.91 | L3MBTL1 (0.44) | L3MBTL1ALDH1A1HTR2AKMT2AMEN1 | |
| SCHEMBL2959801 | 0.89 | L3MBTL1 (0.52) | L3MBTL1ALDH1A1HTR2AKMT2ALMNA | |
| SCHEMBL2961042 | 0.89 | L3MBTL1 (0.44) | L3MBTL1ALDH1A1KMT2AMEN1LMNA | |
| SCHEMBL2958214 | 0.89 | L3MBTL1 (0.47) | L3MBTL1ALDH1A1HTR2AKMT2AMEN1 | |
| SCHEMBL2958211 | 0.87 | L3MBTL1 (0.44) | L3MBTL1ALDH1A1LMNAKDM4EMAPT | |
| SCHEMBL2953460 | 0.83 | L3MBTL1 (0.46) | L3MBTL1ALDH1A1HTR2AKMT2AMEN1 | |
| SCHEMBL6589050 | 0.81 | HSP90AA1 (0.35) | ALDH1A1LMNAKDM4EMAPTP2RY14 | |
| SCHEMBL6490012 | 0.81 | L3MBTL1 (0.47) | L3MBTL1ALDH1A1KMT2AMEN1LMNA | |
| SCHEMBL2959062 | 0.79 | L3MBTL1 (0.45) | L3MBTL1ALDH1A1KMT2AMEN1LMNA | |
| SCHEMBL6479318 | 0.78 | L3MBTL1 (0.48) | L3MBTL1ALDH1A1HTR2AKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7754866-B2 | Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof | ARENA PHARMACEUTICALS, INC. (US) | 2010-07-13 | — | — | US | disclosed |
| US-20090076254-A1 | NON-ENDOGENOUS, CONSTITUTIVELY ACTIVATED HUMAN SEROTONIN RECEPTORS AND SMALL MOLECULE MODULATORS THEREOF | ARENA PHARMACEUTICALS INC. | 2009-03-19 | — | — | US | disclosed |
| US-7368539-B2 | Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof | ARENA PHARMACEUTICALS, INC. (US) | 2008-05-06 | — | — | US | disclosed |
| US-20050119182-A1 | Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof | ARENA PHARMACEUTICALS, INC. (US) | 2005-06-02 | — | — | US | disclosed |
| US-6846919-B2 | Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof | ARENA PHARMACEUTICALS, INC. (US) | 2005-01-25 | — | — | US | disclosed |
| US-20030224442-A1 | Non-endogeneous, constitutively activated human serotonin receptors and small molecule modualtors thereof | BEHAN DOMINIC P (US) | 2003-12-04 | — | — | US | disclosed |
| US-20030153004-A1 | Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof | ARENA PHARMACEUTICALS, INC. | 2003-08-14 | — | — | US | disclosed |
| US-6541209-B1 | Bioassay; identification of compounds as agonists; use in treatment of diseases and disorders that are related to 5-HT2A and or 5-HT2C serotonin receptors | ARENA PHARMACEUTICALS, INC. | 2003-04-01 | — | — | US | disclosed |
| US-6420541-B1 | MEMBRANE PROTEIN FOR USE IN TREATING PSYCHOLOGICAL, NERVOUS SYSTEM, EATING AND SEXUAL DISORDERS | ARENA PHARMACEUTICALS, INC. | 2002-07-16 | — | — | US | disclosed |
| US-6150393-A | N-(3-(4-BROMO-1-METHYLPYRAZOL-3-YL)PHENYL)(PHENYLMETHYLAMINO) -CARBOXAMIDE MODIFIER OF ACTIVITY OF THE SEROTONIN 5-HT 2A; CNS, GASTROINTESTINAL AND CARDIOVASCULAR DISORDERS; ANTIINFLAMMATORY AGENTS; SIDE EFFECT REDUCTION | ARENA PHARMACEUTICALS, INC. (US) | 2000-11-21 | — | — | US | disclosed |
| US-6140509-A | Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof | ARENA PHARMACEUTICALS, INC. (US) | 2000-10-31 | — | — | US | disclosed |
| US-6107324-A | CONTROLLING SEROTONIN | ARENA PHARMACEUTICALS INC. (US) | 2000-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119182-A1 | Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof | HTR2A, HTR3B, HTR3A | L3MBTL1 4160/4885ALDH1A1 3499/4885HTR2A 1/4885 |
| US-20030153004-A1 | Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof | HTR2A, HTR3B, HTR6 | L3MBTL1 4246/4885ALDH1A1 3459/4885HTR2A 1/4885 |
| US-20030224442-A1 | Non-endogeneous, constitutively activated human serotonin receptors and small molecule modualtors thereof | HTR2A, HTR5A, HTR1A | L3MBTL1 2801/4885ALDH1A1 3419/4885HTR2A 1/4885 |
| US-20090076254-A1 | NON-ENDOGENOUS, CONSTITUTIVELY ACTIVATED HUMAN SEROTONIN RECEPTORS AND SMALL MOLECULE MODULATORS THEREOF | HTR2A, HTR3B, HTR3A | L3MBTL1 4160/4885ALDH1A1 3499/4885HTR2A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.